Iridex Announces Third Quarter 2021 Financial Results

Rhea-AI Summary

Iridex Corporation (Nasdaq: IRIX) reported a robust 51% year-over-year revenue growth for Q3 2021, reaching $13.3 million. The gross margin improved to 43.6%, aided by production efficiencies. Despite the positive revenue results, the company experienced a net loss of $2.2 million, which increased compared to the previous year. The revenue guidance for 2021 has been raised to $52 million-$53 million, reflecting a 43%-46% growth, though expectations for Glaucoma Laser System sales have been adjusted downwards.

Positive

• 51% increase in revenue to $13.3 million.
• Gross margin improved to 43.6%, up from 41.5%.
• Retina product revenue surged 76% year-over-year to $7.8 million.
• Revised revenue guidance for 2021 increased to $52-$53 million, signaling strong growth.

Negative

• Net loss increased to $2.2 million from $1.7 million year-over-year.
• Glaucoma Laser System sales expectations reduced to 210-225, down from 250-275.

Achieved 51% Year-over-Year Revenue Growth and Raises 2021 Revenue Guidance

MOUNTAIN VIEW, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended October 2, 2021.

Third Quarter Highlights

• Revenue of $13.3 million, an increase of 51% from the prior year period, and 24% compared to third quarter 2019
  • Gross margin of 43.6%, an improvement over 41.5% in the same period last year
  • Cash usage of $0.7 million leading to cash at quarter-end of $25.6 million
• Cyclo G6^® product family revenue of $3.1 million, an increase of 13% year-over-year
  • 13,400 Cyclo G6 probes sold, an 18% increase year-over-year
  • 42 Cyclo G6 Glaucoma Laser Systems sold, compared to 37 in the prior year period
• Retina product revenue increased 76% year-over-year to $7.8 million
  • PASCAL^® products acquired from Topcon contributed 24% of retina revenue
• MicroPulse^® TLT Clinical Consensus Webinar presented on November 6, featured ten global KOLs highlighting broad patient applicablilty and effective procedure parameters
  

“Strong third quarter results reflect our renewed focus on sales and marketing activities, including major clinical education programs, contributions from our broader distribution partnerships, and several product enhancements, all of which are designed to raise awareness and drive increased adoption in our retina and glaucoma treatment segments,” said David I. Bruce, President and CEO of Iridex. “Cyclo G6 probe sales year-over-year were strong even in a seasonally weaker quarter for ophthalmologic procedures. Additionally, our retina business continues to perform well, thanks to our restructuring of the US sales team to dedicated retina and glaucoma teams, strong contributions from PASCAL products, and our expanded international distribution network. Importantly, our increased operating investments were covered by the quarter’s business strength, limiting cash usage to under $1 million.”

Third Quarter 2021 Financial Results
Revenue for the three months ending October 2, 2021 increased 51% to $13.3 million from $8.8 million during the same period of the prior year. Excluding newly acquired PASCAL products, revenue increased 29% over the third quarter of 2020.

Gross profit for the third quarter of 2021 increased to $5.8 million, a 43.6% gross margin, compared to $3.7 million, a 41.5% gross margin, in the same period last year. The gross margin increase was primarily attributable to the impact of production efficiency initiatives, greater overhead absorption due to higher revenue and continued increase in higher margin probes within the product mix.

Operating expenses for the third quarter of 2021 increased 44% to $7.9 million compared to $5.5 million in the same period of the prior year, mainly due to additional expenses in R&D resulting from absorbing the PASCAL product line and increased activity in Sales & Marketing.

Net loss for the third quarter of 2021 was $2.2 million, compared to a net loss $1.7 million in the same period of the prior year. Net loss on a per share basis was $0.14 in 2021 versus a loss of $0.12 in the third quarter of 2020.

Cash usage in the third quarter was $0.7 million, which resulted in cash of $25.6 million at quarter-end.

Updated Guidance for Full Year 2021
Iridex now expects total revenue for fiscal year 2021 to range from $52 million to $53 million, reflecting growth of 43% - 46% over fiscal year 2020. This compares to the previous range of $50 million to $52 million. Glaucoma Laser System sales are now expected to range from 210 to 225 compared to prior guidance of 250 to 275. Cyclo G6 probe sales expectation of 58,000 to 60,000 remains unchanged.

Webcast and Conference Call Information
Iridex’s management team will host a conference call today beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 7496524. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website: www.iridex.com.

About Iridex
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.

Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the future momentum, demand and utilization of the Company's products, financial guidance, expected sales volumes and benefits from the Topcon partnership. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Quarterly Report on Form 10-Q for the second quarter, filed with the Securities and Exchange Commission on August 12, 2021. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

Investor Relations Contact
Leigh Salvo
(415) 937-5404
investors@iridex.com

IRIDEX Corporation
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
(unaudited)

		Three Months Ended								Nine Months Ended
		October 2,				September 26,				October 2,				September 26,
		2021				2020				2021				2020
Total revenues		$	13,264			$	8,803			$	38,649			$	24,043
Cost of revenues			7,482				5,149				21,820				14,067
Gross profit			5,782				3,654				16,829				9,976
Operating expenses:
Research and development			1,788				869				4,625				2,395
Sales and marketing			3,914				2,959				10,542				8,804
General and administrative			2,237				1,672				6,798				5,060
Total operating expenses			7,939				5,500				21,965				16,259
Loss from operations			(2,157	)			(1,846	)			(5,136	)			(6,283	)
Other income, net			-				135				2,378				153
Loss from operations before provision for income taxes			(2,157	)			(1,711	)			(2,758	)			(6,130	)
Provision for income taxes			8				8				24				20
Net loss		$	(2,165	)		$	(1,719	)		$	(2,782	)		$	(6,150	)
Net loss per share:
Basic		$	(0.14	)		$	(0.12	)		$	(0.18	)		$	(0.44	)
Diluted		$	(0.14	)		$	(0.12	)		$	(0.18	)		$	(0.44	)
Weighted average shares used in computing net loss per share:
Basic			15,824				13,893				15,272				13,824
Diluted			15,824				13,893				15,272				13,824

IRIDEX Corporation
Condensed Consolidated Balance Sheets
(In thousands and unaudited)

		October 2,				January 2,
		2021				2021
Assets
Current assets:
Cash and cash equivalents		$	25,568			$	11,626
Accounts receivable, net			8,522				7,289
Inventories			8,791				5,714
Prepaid expenses and other current assets			1,025				730
Total current assets			43,906				25,359
Property and equipment, net			567				449
Intangible assets, net			2,253				68
Goodwill			965				533
Operating lease right-of-use assets, net			2,794				1,428
Other long-term assets			57				132
Total assets		$	50,542			$	27,969
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable		$	3,208			$	1,148
Accrued compensation			2,683				1,965
Accrued expenses			1,551				990
Other current expenses			2,256				816
Current portion of PPP loan			-				1249
Accrued warranty			99				166
Deferred revenue			2,250				938
Operating lease liabilities			920				1,409
Total current liabilities			12,967				8,681
Long-term liabilities:
PPP Loan			-				1,248
Accrued warranty			60				81
Deferred revenue			10,199				289
Operating lease liabilities			1,972				282
Other long-term liabilities			22				22
Total liabilities			25,220				10,603
Stockholders' equity:
Common stock			168				148
Additional paid-in capital			84,851				74,181
Accumulated other comprehensive income (loss)			29				(19	)
Accumulated deficit			(59,726	)			(56,944	)
Total stockholders' equity			25,322				17,366
Total liabilities and stockholders' equity		$	50,542			$	27,969

 

FAQ

What were Iridex's Q3 2021 revenue results?

Iridex reported Q3 2021 revenue of $13.3 million, marking a 51% increase year-over-year.

What is Iridex's guidance for full year 2021 revenue?

Iridex now expects total revenue for fiscal year 2021 to range from $52 million to $53 million.

How did Iridex's gross margin change in Q3 2021?

The gross margin improved to 43.6% in Q3 2021, up from 41.5% in the prior year.

What was the net loss reported by Iridex in Q3 2021?

Iridex reported a net loss of $2.2 million for Q3 2021, compared to a loss of $1.7 million in the previous year.

How many Glaucoma Laser Systems does Iridex expect to sell in 2021?

Iridex has adjusted its expected sales of Glaucoma Laser Systems to a range of 210 to 225 for 2021.